Brainstorm to present als phase 3 biomarker analyses at annual neals meeting october 6th, 2021

New york, oct. 6, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "csf biomarker correlations with primary outcome in nurown phase 3 clinical trial" will be presented as a scientific poster at the fully digital 2021 northeast amyotrophic lateral sclerosis consortium® (neals) conference.  the presentation will be delivered by james berry, m.d.
BCLI Ratings Summary
BCLI Quant Ranking